FDA Approves First New ADHD Medication Class in Years
The FDA approved a new first-in-class medication for ADHD on July 29, 2026. The drug works through a different mechanism than existing stimulant-based treatments. Doctors say it could offer an option for patients who do not respond well to current medications.
The U.S. Food and Drug Administration approved a new first-in-class medication for attention-deficit/hyperactivity disorder on July 29, 2026, according to Healthline.
The drug uses a different mechanism than the stimulant-based medications that have dominated ADHD treatment for decades. Regulators said the approval gives doctors and patients a new option, particularly for those who experience side effects or limited results from existing treatments.
Details about the drug's name and manufacturer were reported by Healthline as part of its daily health news coverage. The FDA's approval followed clinical trials that demonstrated the medication's effectiveness in reducing ADHD symptoms in adults and children.
ADHD affects an estimated 10% of children and 4% of adults in the United States. Current first-line treatments include stimulants such as amphetamines and methylphenidate, which have been in use since the 1950s.
Non-stimulant options have existed for years but have generally been considered less effective than stimulants for most patients. Physicians said the new approval could expand treatment choices for patients who cannot tolerate stimulants due to cardiovascular concerns or other conditions.
The FDA said it would continue to monitor the drug's safety profile after approval.
